C4 Therapeutics, Inc. Contract with Customer, Performance Obligation Satisfied in Previous Period
C4 Therapeutics, Inc. (CCCC) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $1.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-02-26
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-12-31 was $0.00.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-09-30 was $43.00K.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $1.34M.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $43.00K, a 91.70% decline from fiscal 2022.
- C4 Therapeutics, Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $518.00K, a 68.68% decline from fiscal 2021.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.34M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $43.00K derived: sum of 2 quarters · filed 2025-02-27 | $43.00K derived: sum of 3 quarters · filed 2025-02-27 | $43.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $43.00K 10-Q · filed 2023-11-01 | $43.00K derived: sum of 2 quarters · filed 2023-11-01 | $43.00K 10-Q · filed 2023-11-01 | $43.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $503.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $503.00K derived: sum of 3 quarters · filed 2024-02-22 | $518.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | $503.00K derived: sum of 2 quarters · filed 2023-11-01 | $518.00K 10-Q · filed 2023-11-01 | $1.56M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $503.00K 10-Q · filed 2023-08-08 | $518.00K 10-Q · filed 2023-08-08 | $1.56M derived: sum of 3 quarters · filed 2023-08-08 | $1.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $115.00K 10-Q · filed 2023-05-04 | $1.06M derived: sum of 2 quarters · filed 2023-05-04 | $1.06M derived: sum of 3 quarters · filed 2023-05-04 | $1.77M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $941.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $941.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.65M derived: sum of 3 quarters · filed 2023-02-23 | $1.65M 10-K · filed 2023-02-23 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $713.00K derived: sum of 2 quarters · filed 2022-11-03 | $713.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $713.00K 10-Q · filed 2022-08-04 | $713.00K 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $121.00K derived: sum of 2 quarters · filed 2022-02-24 | $348.00K derived: sum of 3 quarters · filed 2022-02-24 | $348.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $227.00K derived: sum of 2 quarters · filed 2021-11-10 | $227.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $227.00K 10-Q · filed 2021-08-11 | $227.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |